EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma

Doyun Kim iD, Yunsung Jo iD, Seonghoon Kim iD, Mihyun Choi iD, Yongsun Kim iD

Journal of Veterinary Internal Medicine · 02.03.2026 · 40 (2)

DOI: 10.1093/jvimsj/aalag075 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 22.04.2026. Verfasst von Doyun Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, BON Animal Medical Center, Suwon 16305, Republic of Korea. Hauptthemen laut MEDLINE: Dog Diseases, Niacinamide, Sarcoma, Antineoplastic Agents. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sorafenib is a multi-kinase inhibitor increasingly used in veterinary oncology, but information regarding its potential adverse hematologic effects in dogs remains limited. A 50 kg neutered male Labrador Retriever with previously treated intranasal sarcoma was treated with sorafenib (5 mg/kg PO q24h) based on tyrosine kinase receptor profiling that identified 60% overexpression of platelet-derived growth factor receptor. The dog remained clinically stable for 132 days before developing worsening nasal discharge, increased epistaxis, and respiratory effort. Hematologic testing identified a platelet count of 130 × 103/μL with clumping, normal prothrombin time, activated partial thromboplastin time, and normal D-dimer concentration. Computed tomography did not indicate appreciable tumor progression. Viscoelastic assessment demonstrated delayed clot initiation and markedly decreased clot development and firmness, consistent with a hypocoagulable profile. Sorafenib was discontinued, and serial viscoelastic testing on days 149, 170, and 191 showed progressive improvement with normalization of clot parameters, paralleling the resolution of clinical signs. This case documents reversible, sorafenib-associated coagulopathy in a dog and illustrates the diagnostic utility of viscoelastic testing when evaluating worsening epistaxis in dogs receiving tyrosine kinase inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesNiacinamideSarcomaAntineoplastic AgentsNose NeoplasmsPhenylurea CompoundsBlood Coagulation DisordersAnimalsDogsSorafenibMale

Stichwörter der Autor:innen

canine nasal tumorcoagulopathysorafenibtyrosine kinase inhibitorviscoelastic testing

Substanzen

SorafenibNiacinamideAntineoplastic AgentsPhenylurea Compounds

Autor:innen und Institutionen

  • Department of Oncology, BON Animal Medical Center, Suwon 16305, Republic of Korea.

ORCID-Profile: Doyun Kim, Yunsung Jo, Seonghoon Kim, Mihyun Choi, Yongsun Kim

Zitieren

APA

Kim, D., Jo, Y., Kim, S., Choi, M., & Kim, Y. (2026). Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma. Journal of Veterinary Internal Medicine, 40(2). https://doi.org/10.1093/jvimsj/aalag075

Vancouver

Kim D, Jo Y, Kim S, Choi M, Kim Y. Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma. Journal of Veterinary Internal Medicine. 2026;40(2). doi:10.1093/jvimsj/aalag075

BibTeX
@article{Kim2026,
  author = {Kim, Doyun and Jo, Yunsung and Kim, Seonghoon and Choi, Mihyun and Kim, Yongsun},
  title = {Reversible sorafenib-associated coagulopathy identified by viscoelastic testing in a dog with intranasal sarcoma},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {2},
  doi = {10.1093/jvimsj/aalag075}
}
Kostenlos starten →